{"entity":{"type":"insider","cik":"0001390331","url":"/insider/0001390331","json_url":"/insider/0001390331.json","name":"Highbridge Convertible Arbitrage Master Fund, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":14,"n_filings":6,"first":"2007-02-20","last":"2007-08-15","span_basis":"filed_date"},"name_variants":[{"name":"Highbridge Convertible Arbitrage Master Fund, L.P.","source":"filing","n_filings":6,"first_seen":"2007-02-20","last_seen":"2007-08-15"}],"transactions":[{"id":7683568,"accession":"0000902664-07-002650","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000902664-07-002650","line_url":"/filing/0000902664-07-002650","is_derivative":false,"issuer_cik":"0000727510","issuer_name":"ENZON PHARMACEUTICALS INC","issuer_ticker":"ENZN","issuer_name_source":null,"issuer_url":"/issuer/0000727510","owner_cik":null,"owner_name":"HIGHBRIDGE CAPITAL MANAGEMENT LLC; Swieca Henry; Highbridge Convertible Arbitrage Master Fund, L.P.; Dubin Glenn; Highbridge International LLC","owner_display_name":"HIGHBRIDGE CAPITAL MANAGEMENT LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Shares of common stock, $0.01 par (\"Common Stock\")","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":102343.0,"shares_display":"102,343","price_per_share":6.503969787870201,"price_display":"6.50","price_state":"stated","total_value":665635.78,"total_display":"665,635.78","total_whole":"665,636","shares_owned_after":2343.0,"shares_owned_after_display":"2,343","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-08-13","filed_date":"2007-08-15","scope":"insider","n_lines":3},{"id":7255212,"accession":"0000902664-07-002431","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000902664-07-002431","line_url":"/filing/0000902664-07-002431#line-2","is_derivative":false,"issuer_cik":"0000727510","issuer_name":"ENZON PHARMACEUTICALS INC","issuer_ticker":"ENZN","issuer_name_source":null,"issuer_url":"/issuer/0000727510","owner_cik":null,"owner_name":"Swieca Henry; Highbridge Convertible Arbitrage Master Fund, L.P.; HIGHBRIDGE CAPITAL MANAGEMENT LLC; Highbridge International LLC; Dubin Glenn","owner_display_name":"Swieca Henry","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Shares of common stock, $0.01 par (\"Common Stock\")","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":60000.0,"shares_display":"60,000","price_per_share":7.21,"price_display":"7.21","price_state":"stated","total_value":432600.0,"total_display":"432,600.00","total_whole":"432,600","shares_owned_after":60000.0,"shares_owned_after_display":"60,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-08-02","filed_date":"2007-08-06","scope":"insider"},{"id":7683554,"accession":"0000902664-07-002341","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000902664-07-002341","line_url":"/filing/0000902664-07-002341#line-2","is_derivative":false,"issuer_cik":"0000727510","issuer_name":"ENZON PHARMACEUTICALS INC","issuer_ticker":"ENZN","issuer_name_source":null,"issuer_url":"/issuer/0000727510","owner_cik":null,"owner_name":"Highbridge Convertible Arbitrage Master Fund, L.P.; Highbridge International LLC; Dubin Glenn; Swieca Henry; HIGHBRIDGE CAPITAL MANAGEMENT LLC","owner_display_name":"Highbridge Convertible Arbitrage Master Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Shrs. of common stock $0.01 par val. per shr. (Common Stock)","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":55000.0,"shares_display":"55,000","price_per_share":7.71,"price_display":"7.71","price_state":"stated","total_value":424050.0,"total_display":"424,050.00","total_whole":"424,050","shares_owned_after":55000.0,"shares_owned_after_display":"55,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-07-24","filed_date":"2007-07-26","scope":"insider"},{"id":7335726,"accession":"0000902664-07-002298","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000902664-07-002298","line_url":"/filing/0000902664-07-002298#line-2","is_derivative":false,"issuer_cik":"0000727510","issuer_name":"ENZON PHARMACEUTICALS INC","issuer_ticker":"ENZN","issuer_name_source":null,"issuer_url":"/issuer/0000727510","owner_cik":null,"owner_name":"Highbridge International LLC; HIGHBRIDGE CAPITAL MANAGEMENT LLC; Dubin Glenn; Highbridge Convertible Arbitrage Master Fund, L.P.; Swieca Henry","owner_display_name":"Highbridge International LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Shares of common stock, $0.01 par value (\"Common Stock\")","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":22192.0,"shares_display":"22,192","price_per_share":7.75,"price_display":"7.75","price_state":"stated","total_value":171988.0,"total_display":"171,988.00","total_whole":"171,988","shares_owned_after":22192.0,"shares_owned_after_display":"22,192","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-07-16","filed_date":"2007-07-18","scope":"insider"},{"id":7941049,"accession":"0000902664-07-002279","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000902664-07-002279","line_url":"/filing/0000902664-07-002279#line-4","is_derivative":false,"issuer_cik":"0000727510","issuer_name":"ENZON PHARMACEUTICALS INC","issuer_ticker":"ENZN","issuer_name_source":null,"issuer_url":"/issuer/0000727510","owner_cik":null,"owner_name":"Swieca Henry; HIGHBRIDGE CAPITAL MANAGEMENT LLC; Highbridge International LLC; Highbridge Convertible Arbitrage Master Fund, L.P.; Dubin Glenn","owner_display_name":"Swieca Henry","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":7.71,"price_display":"7.71","price_state":"stated","total_value":3855.0,"total_display":"3,855.00","total_whole":"3,855","shares_owned_after":500.0,"shares_owned_after_display":"500","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-07-12","filed_date":"2007-07-13","scope":"insider"},{"id":7941045,"accession":"0000902664-07-002279","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000902664-07-002279","line_url":"/filing/0000902664-07-002279#line-2","is_derivative":false,"issuer_cik":"0000727510","issuer_name":"ENZON PHARMACEUTICALS INC","issuer_ticker":"ENZN","issuer_name_source":null,"issuer_url":"/issuer/0000727510","owner_cik":null,"owner_name":"Swieca Henry; HIGHBRIDGE CAPITAL MANAGEMENT LLC; Highbridge International LLC; Highbridge Convertible Arbitrage Master Fund, L.P.; Dubin Glenn","owner_display_name":"Swieca Henry","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Shares of common stock, $0.01 par value (\"Common Stock\")","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":54013.0,"shares_display":"54,013","price_per_share":7.73,"price_display":"7.73","price_state":"stated","total_value":417520.49,"total_display":"417,520.49","total_whole":"417,520","shares_owned_after":54013.0,"shares_owned_after_display":"54,013","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-07-11","filed_date":"2007-07-13","scope":"insider"},{"id":8538341,"accession":"0000902664-07-001053","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0000902664-07-001053","line_url":"/filing/0000902664-07-001053","is_derivative":false,"issuer_cik":"0000727510","issuer_name":"ENZON PHARMACEUTICALS INC","issuer_ticker":"ENZN","issuer_name_source":null,"issuer_url":"/issuer/0000727510","owner_cik":null,"owner_name":"Highbridge International LLC; HIGHBRIDGE CAPITAL CORP; HIGHBRIDGE CAPITAL MANAGEMENT LLC; Dubin Glenn; Highbridge Convertible Arbitrage Master Fund, L.P.; Swieca Henry","owner_display_name":"Highbridge International LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Shares of common stock, $0.01 par value (\"Common Stock\")","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":68910.0,"shares_display":"68,910","price_per_share":8.705143085183574,"price_display":"8.71","price_state":"stated","total_value":599871.41,"total_display":"599,871.41","total_whole":"599,871","shares_owned_after":30000.0,"shares_owned_after_display":"30,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-02-15","filed_date":"2007-02-20","scope":"insider","n_lines":6}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000727510","name":"ENZON PHARMACEUTICALS INC","url":"/issuer/0000727510","role":"Ten percent owner","n_filings":6,"first_seen":"2007-02-20","last_seen":"2007-08-15"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001390331","retrieved_at":"2026-08-22T21:12:01+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}